share_log

Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12

Benzinga ·  Dec 19 20:43  · Ratings

Wells Fargo analyst Derek Archila upgrades C4 Therapeutics (NASDAQ:CCCC) from Equal-Weight to Overweight and raises the price target from $8 to $12.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment